image
Healthcare - Biotechnology - NASDAQ - US
$ 4.07
-3.78 %
$ 16 M
Market Cap
-0.4
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CING stock under the worst case scenario is HIDDEN Compared to the current market price of 4.07 USD, Cingulate Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CING stock under the base case scenario is HIDDEN Compared to the current market price of 4.07 USD, Cingulate Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CING stock under the best case scenario is HIDDEN Compared to the current market price of 4.07 USD, Cingulate Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CING

image
$5.2$5.2$5.0$5.0$4.8$4.8$4.6$4.6$4.4$4.4$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-15.6 M OPERATING INCOME
31.26%
-15.5 M NET INCOME
100.00%
-18.5 M OPERATING CASH FLOW
-22.72%
-212 K INVESTING CASH FLOW
5.36%
30.8 M FINANCING CASH FLOW
209.61%
0 REVENUE
0.00%
-6.21 M OPERATING INCOME
99.91%
-6.13 M NET INCOME
-89.75%
-4.08 M OPERATING CASH FLOW
99.97%
-198 K INVESTING CASH FLOW
-140.96%
6.45 M FINANCING CASH FLOW
-51.88%
Balance Sheet Cingulate Inc.
image
Current Assets 12.7 M
Cash & Short-Term Investments 12.2 M
Receivables 26.3 K
Other Current Assets 423 K
Non-Current Assets 2.2 M
Long-Term Investments 0
PP&E 2.2 M
Other Non-Current Assets 0
82.15 %2.85 %14.83 %Total Assets$14.9m
Current Liabilities 4.97 M
Accounts Payable 1.27 M
Short-Term Debt 2.66 M
Other Current Liabilities 1.04 M
Non-Current Liabilities 2.44 M
Long-Term Debt 2.44 M
Other Non-Current Liabilities 0
17.15 %35.93 %14.03 %32.89 %Total Liabilities$7.4m
EFFICIENCY
Earnings Waterfall Cingulate Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 15.6 M
Operating Income -15.6 M
Other Expenses -99 K
Net Income -15.5 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)000(16m)(16m)99k(16m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-208.52% ROE
-208.52%
-104.58% ROA
-104.58%
-124.62% ROIC
-124.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cingulate Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)202020202021202120222022202320232024202420252025
Net Income -15.5 M
Depreciation & Amortization -198 K
Capital Expenditures -212 K
Stock-Based Compensation 0
Change in Working Capital 0
Others -23 M
Free Cash Flow -18.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cingulate Inc.
image
CING has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Cingulate Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
841 USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide globenewswire.com - 3 weeks ago
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission globenewswire.com - 1 month ago
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million. globenewswire.com - 4 months ago
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 globenewswire.com - 5 months ago
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate's lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company's PTR™ technology may be applied. globenewswire.com - 6 months ago
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 $10 Million of additional Capital Recently Raised Strengthening Balance Sheet $10 Million of additional Capital Recently Raised Strengthening Balance Sheet globenewswire.com - 7 months ago
Cingulate to Participate in Benzinga All Live Access Event KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. globenewswire.com - 8 months ago
Cingulate Announces Adjournment of Special Meeting KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals. globenewswire.com - 8 months ago
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy? Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment. invezz.com - 8 months ago
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. benzinga.com - 8 months ago
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it was issued a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). globenewswire.com - 8 months ago
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025 Licensing Activity Continues globenewswire.com - 8 months ago
8. Profile Summary

Cingulate Inc. CING

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 16 M
Dividend Yield 0.00%
Description Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Contact 1901 West 47th Place, Kansas City, KS, 66205 https://www.cingulate.com
IPO Date Dec. 8, 2021
Employees 13
Officers Thomas Dalton Vice President of Investor & Public Relations Dr. Shane J. Schaffer Pharm.D. Co-Founder, Chief Executive Officer & Chairman of the Board Dr. Laurie A. Myers M.B.A., Ph.D. Executive Vice President & Chief Operating Officer Dr. Raul R. Silva M.D. Co-Founder, Executive Vice President & Chief Science Officer Ms. Jennifer L. Callahan CPA Senior Vice President, Chief Financial Officer & Secretary Dr. Matthew N. Brams M.D. Co-Founder, Executive Vice President & Chief Medical Officer